A phase I study of low dose interleukin 2 (IL-2) monotherapy, followed by IL-2 plus PEG-IFN/RBV [pegylated interferon alpha/ ribavirin] in chronic hepatitis C virus genotype I infection
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Interleukin-2; Peginterferon alfa; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions
- 24 Mar 2009 Actual patient number (18) added as reported by ClinicalTrials.gov.
- 24 Mar 2009 Actual initiation date (Mar 2004) added as reported by ClinicalTrials.gov.
- 24 Mar 2009 Planned end date (Aug 2006) added as reported by ClinicalTrials.gov.